One of the more popular sessions at this year's American College of Cardiology 62nd Annual Scientific Session and Expo featured a discussion on regulatory oversight and the need for better protection of patients' interests.
One of the more popular sessions at this year’s American College of Cardiology 62nd Annual Scientific Session and Expo featured a discussion on regulatory oversight and the need for better protection of patients’ interests. Among the speakers in this discussion was Robert G. Hauser, MD, FACC, who spoke about how the US Food and Drug Administration (FDA) and Congress are not doing enough to protect patients, as well as what he believes can and should be done to do so.
Dr Hauser began his presentation by rattling off 3 essential components to protecting patients:
Unfortunately, the FDA and Congress have both failed to deliver the types of approval processes, post-marketing surveillance, and recall management that Dr Hauser described. Major problems still exist in the area of post-marketing surveillance, according to Dr Hauser. While this process is supposed to enhance public health by reducing the amount of adverse events due to drugs or medical devices, the fact is that, despite multiple recalls in recent years (and some tragic events), patients in the United States continue to be exposed to hazardous drugs and defective or underperforming devices after they have been approved by the FDA. Dr Hauser illustrated this point by featuring a slide of drugs and devices—including rofecoxib (Vioxx), Sprint Fidelis (ICD lead), rosiglitazone (Avandia), and others—that were FDA approved at one point but then removed from the market (often times 5 or more years later) due to adverse events, such as strokes and fractures. Why does this happen? “Because the FDA is a passive regulator,” says Dr Hauser, who also points out that none of the 3510 medical device recalls from 2005 to 2009 were mandated by the FDA. In some cases, recalls took place after a product had been removed from the market, meaning that manufacturers set the patient safety agenda.
Dr Hauser believes that the FDA can learn a thing or two from the airline industry, and he points out that, since the last airline crash on September 11, 2001, there have been no fatal major US airlines crashes, and this includes 93 million flights with more than 6.5 billion passengers. The reason for this success rate, says Dr Hauser, is that the Federal Aviation Administration (FAA) and the National Transportation Safety Board (NTSB) not only have a passion for safety, but also separate but complementary roles. The FAA is responsible for regulation and operating the aviation system, whereas the NTSB investigates accidents and makes safety recommendations. And, even though the NTSB has no regulatory authority, they do report directly to Congress and operate independently of both the FAA and Department of Transportation. The NTSB operates independently because Congress established the organization in 1974 specifically because “no federal agency can properly perform investigatory functions unless it is totally separate and independent.”
Dr Hauser would like to see this model adopted by the FDA. There is a great need for an independent national drug and device safety board to identify safety issues, investigate adverse events, provide recommendations based on findings, and share information with all stakeholders. Until this occurs, patients will continue to believe that drugs and devices that are “FDA Approved” are, in fact, safe and effective, when this is not true. Dr Hauser believes that there is much work to be done in order to make that belief a reality.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More